# Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Source: https://onco.cc/trials/nct03767348/  
OnCo record `nct03767348` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Replimune, Inc., active and no longer recruiting.

## Summary

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) is a phase 2 interventional study registered as NCT03767348 by Replimune, Inc., with 340 participants planned, started 2017-09-20 and due to reach its primary completion in 2028-06. Interventions recorded: RP1, nivolumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03767348
- Phase: 2
- Setting: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
- Sponsor: Replimune, Inc.
- Enrolled: 340

## Sources

- ClinicalTrials.gov NCT03767348: https://clinicaltrials.gov/study/NCT03767348

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Replimune](https://onco.cc/companies/replimune/)

---
JSON: https://onco.cc/api/v1/entities/nct03767348.json